Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598791 | 0.96 | HTR4 (0.50) | HTR4CYP3A4GLAHSD17B10MEN1 | |
| SCHEMBL598670 | 0.91 | HTR4 (0.52) | HTR4CYP3A4GLAHSD17B10MEN1 | |
| SCHEMBL598877 | 0.84 | GAA (0.45) | HTR4HSD17B10MEN1ALDH1A1KMT2A | |
| SCHEMBL597813 | 0.84 | ACHE (0.39) | HTR4HSD17B10MEN1ALDH1A1HTR3A | |
| Hydrochloric Acid SCHEMBL599362 | 0.83 | ALDH1A1 (0.45) | HSD17B10MEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL598675 | 0.83 | ACHE (0.39) | HTR4HSD17B10MEN1ALDH1A1HTR3A | |
| SCHEMBL599132 | 0.81 | KMT2A (0.47) | HSD17B10MEN1ALDH1A1KMT2A | |
| SCHEMBL598811 | 0.81 | HTR4 (0.41) | HTR4HSD17B10MEN1ALDH1A1KMT2A | |
| SCHEMBL598054 | 0.80 | PKM (0.43) | HSD17B10MEN1ALDH1A1HTR3AKMT2A | |
| Hydrochloric Acid SCHEMBL598946 | 0.80 | HTR4 (0.41) | HTR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | claimed |
| EP-2445877-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Nanotherapeutics, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | claimed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | claimed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | NANOTHERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | HTR2C, HTR3A, HTR3C | HTR4 7/4885CYP3A4 517/4885GLA 4365/4885 |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | HTR2C, HTR3A, HTR3C | HTR4 7/4885CYP3A4 517/4885GLA 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.